It's a strong signal but only 7 patients dosed PP in that arm and the other arm had significantly less impressive results (roughly matched placebo...though placebo performed better than normal).

We got burned on Prurisol subgroup analysis so there is management is 0/1 on previous subgroup analysis judgement calls.

There is a reason we didnt get BTD on the current data. It will need to be proven again with greater numbers of patients.

This is why I dont think the first deal will be gigantic. We're desperate and B-OM still has some risk of not reproducing such rosy subgroup analysis numbers.